UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

The New England journal of medicine, 2020-12, Vol.383 (26), p.2526-2537

2020

Link zum Volltext

Verfügbarkeit prüfen

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

The lancet oncology, 2015-09, Vol.16 (9), p.1025-1036

2015

Link zum Volltext

Verfügbarkeit prüfen

Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review

Case reports in hematology, 2018-01, Vol.2018, p.3604298-5

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Journal of hematology and oncology, 2021-08, Vol.14 (1), p.1-133, Article 133

2021

Link zum Volltext

Verfügbarkeit prüfen

Where West Meets East: The Complex mtDNA Landscape of the Southwest and Central Asian Corridor

American journal of human genetics, 2004-05, Vol.74 (5), p.827-845

2004

Link zum Volltext

Verfügbarkeit prüfen

Y-Chromosome Lineages Trace Diffusion of People and Languages in Southwestern Asia

American journal of human genetics, 2001-02, Vol.68 (2), p.537-542

2001

Link zum Volltext

Verfügbarkeit prüfen

Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis

Case reports in hematology, 2015-01, Vol.2015, p.826894-3

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of ethnicity in thrombotic and hemorrhagic complications of myeloproliferative neoplasms

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18555-e18555

2019

Link zum Volltext

Verfügbarkeit prüfen

Therapies for acute myeloid leukemia: vosaroxin

OncoTargets and therapy, 2017-01, Vol.10, p.3957-3963

2017

Link zum Volltext

Verfügbarkeit prüfen

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Blood, 2022-11, Vol.140 (Supplement 1), p.11546-11547

2022

Link zum Volltext

Verfügbarkeit prüfen

Long‐term outcome of NPM1 mutated acute myeloid leukemia: A single‐institution experience

American journal of hematology, 2017-02, Vol.92 (2), p.E17-E18

2017

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.871-871

2021

Link zum Volltext

Verfügbarkeit prüfen

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Blood, 2021-11, Vol.138 (Supplement 1), p.2601-2601

2021

Link zum Volltext

Verfügbarkeit prüfen

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Blood, 2019-11, Vol.134 (Supplement_1), p.5051-5051

2019

Link zum Volltext

Verfügbarkeit prüfen

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

The oncologist (Dayton, Ohio), 2018-02, Vol.23 (2), p.159-170

2018

Link zum Volltext

Verfügbarkeit prüfen

Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms?

Hematology/oncology and stem cell therapy, 2022-06, Vol.15 (2), p.30-38

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 800: Exploiting the proteasome to overcome RAS and WT1 mutation mediated resistance to FLT-3 inhibition in acute myeloid leukemia

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.800-800

2020

Link zum Volltext

Verfügbarkeit prüfen

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Leukemia research, 2019-02, Vol.77, p.30-33

2019

Link zum Volltext

Verfügbarkeit prüfen

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Blood, 2017-12, Vol.130, p.3897-3897

2017

Link zum Volltext

Verfügbarkeit prüfen

Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial

American journal of hematology, 2023-04, Vol.98 (4), p.E84-E87

2023

Link zum Volltext

Verfügbarkeit prüfen

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

Blood advances, 2019-02, Vol.3 (4), p.508-518

2019

Link zum Volltext

Verfügbarkeit prüfen

AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S252-S253

2022

Link zum Volltext

Verfügbarkeit prüfen

Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S125

2022

Link zum Volltext

Verfügbarkeit prüfen

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.7513-7513

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(66)
Berichte
(1)

Sprache

Englisch
(67)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(20)
Male
(16)
Female
(13)
Oncology
(13)
Hematology
(12)
Middle Aged
(11)
Aged
(9)
Leukemia, Myeloid, Acute - Drug Therapy
(9)
Acute Myeloid Leukemia
(8)
Aged, 80 And Over
(7)
Bone Marrow
(7)
Adult
(6)
Aml
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Biological And Medical Sciences
(6)
Chemotherapy
(6)
Leukemia
(6)
Medical Sciences
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Primary Myeloid Sarcoma of the Prostate: A Case Report and Literature Review

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Where West Meets East: The Complex mtDNA Landscape of the Southwest and Central Asian Corridor

Y-Chromosome Lineages Trace Diffusion of People and Languages in Southwestern Asia

Acute Promyelocytic Leukemia Presenting with Severe Marrow Fibrosis

Role of ethnicity in thrombotic and hemorrhagic complications of myeloproliferative neoplasms

Therapies for acute myeloid leukemia: vosaroxin

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Long‐term outcome of NPM1 mutated acute myeloid leukemia: A single‐institution experience

Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms?

Abstract 800: Exploiting the proteasome to overcome RAS and WT1 mutation mediated resistance to FLT-3 inhibition in acute myeloid leukemia

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial

Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial

Suchergebnisse filtern